• Something wrong with this record ?

Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness

I. Procházková, J. Lenčo, A. Fučíková, J. Dresler, L. Čápková, R. Hrstka, R. Nenutil, P. Bouchal,

. 2017 ; 1865 (5) : 488-498. [pub] 20170216

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17031028

Breast cancer is the most common and molecularly relatively well characterized malignant disease in women, however, its progression to metastatic cancer remains lethal for 78% of patients 5years after diagnosis. Novel markers could identify the high risk patients and their verification using quantitative methods is essential to overcome genetic, inter-tumor and intra-tumor variability and translate novel findings into cancer diagnosis and treatment. We recently identified 13 proteins associated with estrogen receptor, tumor grade and lymph node status, the key factors of breast cancer aggressiveness, using untargeted proteomics. Here we verified these findings in the same set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM), transcriptomics and immunohistochemistry and validated in 5 independent sets of 715 patients using transcriptomics. We confirmed: (i) positive association of anterior gradient protein 2 homolog (AGR2) and periostin (POSTN) and negative association of annexin A1 (ANXA1) with estrogen receptor status; (ii) positive association of stathmin (STMN1), cofilin-1 (COF1), plasminogen activator inhibitor 1 RNA-binding protein (PAIRBP1) and negative associations of thrombospondin-2 (TSP2) and POSTN levels with tumor grade; and (iii) positive association of POSTN, alpha-actinin-4 (ACTN4) and STMN1 with lymph node status. This study highlights a panel of gene products that can contribute to breast cancer aggressiveness and metastasis, the understanding of which is important for development of more precise breast cancer treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031028
003      
CZ-PrNML
005      
20190909095648.0
007      
ta
008      
171025s2017 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bbapap.2017.02.012 $2 doi
035    __
$a (PubMed)28216224
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Procházková, Iva $u Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Zluty kopec 7, 65653 Brno, Czech Republic; Masaryk University, Faculty of Science, Department of Biochemistry, Kotlarska 2, 61137 Brno, Czech Republic.
245    10
$a Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness / $c I. Procházková, J. Lenčo, A. Fučíková, J. Dresler, L. Čápková, R. Hrstka, R. Nenutil, P. Bouchal,
520    9_
$a Breast cancer is the most common and molecularly relatively well characterized malignant disease in women, however, its progression to metastatic cancer remains lethal for 78% of patients 5years after diagnosis. Novel markers could identify the high risk patients and their verification using quantitative methods is essential to overcome genetic, inter-tumor and intra-tumor variability and translate novel findings into cancer diagnosis and treatment. We recently identified 13 proteins associated with estrogen receptor, tumor grade and lymph node status, the key factors of breast cancer aggressiveness, using untargeted proteomics. Here we verified these findings in the same set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM), transcriptomics and immunohistochemistry and validated in 5 independent sets of 715 patients using transcriptomics. We confirmed: (i) positive association of anterior gradient protein 2 homolog (AGR2) and periostin (POSTN) and negative association of annexin A1 (ANXA1) with estrogen receptor status; (ii) positive association of stathmin (STMN1), cofilin-1 (COF1), plasminogen activator inhibitor 1 RNA-binding protein (PAIRBP1) and negative associations of thrombospondin-2 (TSP2) and POSTN levels with tumor grade; and (iii) positive association of POSTN, alpha-actinin-4 (ACTN4) and STMN1 with lymph node status. This study highlights a panel of gene products that can contribute to breast cancer aggressiveness and metastasis, the understanding of which is important for development of more precise breast cancer treatment.
650    _2
$a faktory depolymerizující aktin $x biosyntéza $x genetika $7 D051339
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x biosyntéza $x genetika $7 D014408
650    _2
$a nádory prsu $x genetika $x patologie $7 D001943
650    _2
$a molekuly buněčné adheze $x biosyntéza $x genetika $7 D015815
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a lymfatické uzliny $x metabolismus $x patologie $7 D008198
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a lidé středního věku $7 D008875
650    _2
$a invazivní růst nádoru $x genetika $x patologie $7 D009361
650    _2
$a nádorové proteiny $x biosyntéza $x genetika $7 D009363
650    _2
$a prognóza $7 D011379
650    _2
$a proteomika $7 D040901
650    _2
$a proteiny vázající RNA $x biosyntéza $x genetika $7 D016601
650    _2
$a receptory pro estrogeny $x genetika $7 D011960
650    _2
$a stathmin $x biosyntéza $x genetika $7 D050777
650    _2
$a thrombospondiny $x biosyntéza $x genetika $7 D019699
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lenčo, Juraj $u University of Defence, Faculty of Military Health Sciences, Department of Molecular Pathology and Biology, Trebesska 1575, 50001 Hradec Kralove, Czech Republic.
700    1_
$a Fučíková, Alena $u University of Defence, Faculty of Military Health Sciences, Department of Molecular Pathology and Biology, Trebesska 1575, 50001 Hradec Kralove, Czech Republic.
700    1_
$a Dresler, Jiří $u University of Defence, Faculty of Military Health Sciences, Department of Molecular Pathology and Biology, Trebesska 1575, 50001 Hradec Kralove, Czech Republic; Military Health Institute, Tychonova 1, 160 00 Prague, Czech Republic.
700    1_
$a Čápková, Lenka $u Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Zluty kopec 7, 65653 Brno, Czech Republic; Masaryk University, Faculty of Science, Department of Biochemistry, Kotlarska 2, 61137 Brno, Czech Republic.
700    1_
$a Hrstka, Roman $u Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Zluty kopec 7, 65653 Brno, Czech Republic.
700    1_
$a Nenutil, Rudolf $u Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Zluty kopec 7, 65653 Brno, Czech Republic.
700    1_
$a Bouchal, Pavel, $u Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Zluty kopec 7, 65653 Brno, Czech Republic; Masaryk University, Faculty of Science, Department of Biochemistry, Kotlarska 2, 61137 Brno, Czech Republic. Electronic address: bouchal@chemi.muni.cz. $d 1975- $7 xx0128495
773    0_
$w MED00007006 $t Biochimica et biophysica acta. Proteins and proteomics $x 1570-9639 $g Roč. 1865, č. 5 (2017), s. 488-498
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28216224 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20190909100026 $b ABA008
999    __
$a ok $b bmc $g 1254621 $s 992055
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 1865 $c 5 $d 488-498 $e 20170216 $i 1570-9639 $m Biochimica et biophysica acta. Proteins and proteomics $n Biochem Biophys Acta $x MED00007006
LZP    __
$a Pubmed-20171025

Find record

Citation metrics

Archiving options